Please sign in to follow a disease.
Glass dressing aims to heal diabetic foot ulcers faster
NCT ID NCT06403605
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a borate-based bioactive glass wound matrix (Mirragen) plus standard care against standard care alone for diabetic foot ulcers. 148 adults with diabetes and a foot ulcer were enrolled. The main goal was to see if the glass dressing helped more wounds close completely within 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mirragen Advanced Wound Matrix (borate-based bioactive glass)
- What this could lead to
- If successful, this could provide a new option to help diabetic foot ulcers heal faster and more completely.
- What could go wrong
- This is a completed trial, but results are not yet widely known. The device is already commercially available, so the benefit over standard care may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
148 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Jan 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects must be at least 18 years of age or older. 2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus. 3. At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app. 4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit. 5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. 6. The target ulcer must be full thickness on the foot or ankle that does not probe to bone. 7. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit: 1. TCOM ≥30 mmHg 2. ABI between 0.7 and 1.3 3. PVR: Biphasic 4. TBI ˃0.6 5. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle 8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization. 10. The subject must consent to using the prescribed off-loading method for the duration of the study. 11. The subject must agree to attend the weekly study visits required by the protocol. 12. The subject must be willing and able to participate in the informed consent process. Exclusion Criteria: 1. A subject known to have a life expectancy of \< 6 months is excluded. 2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded. 3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence. 4. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. 5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded. 6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted. 7. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer. 8. If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded. 9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded. 10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC. 11. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded. 12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded. 13. A potential subject with end stage renal disease requiring dialysis is excluded. 14. A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded. 15. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded. 16. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic foot are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Casa Colina
Pomona, California, 91769, United States
-
Center for Clincal Research
San Francisco, California, 94115, United States
-
Doctor's Research Network
South Miami, Florida, 33143, United States
-
Foot and Ankle Center of Illinois
Springfield, Illinois, 62704, United States
-
Foot and Ankle Specialists of the Mid Atlantic
Frederick, Maryland, 21703, United States
-
Foot and Ankle Specialists of the Mid Atlantic
Salem, Virginia, 24153, United States
-
Gateway Clinical Trials
O'Fallon, Illinois, 62269, United States
-
LA Foot and Ankle
Los Angeles, California, 90010, United States
-
Lower Extremity Institute for Research and Therapy
Youngstown, Ohio, 44512, United States
-
Mercy Medical Center
Cedar Rapids, Iowa, 52403, United States
-
PULSE: Amputation Prevention Center, LLC
El Paso, Texas, 79902, United States
-
Southernmost Foot and Ankle Specialists
Homestead, Florida, 33030, United States
-
United Wound Healing P.S
Auburn, Washington, 98092, United States
-
Wound Care Experts
Las Vegas, Nevada, 89148, United States
-
Wound Centrics
Corpus Christi, Texas, 78404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy shots aim to save legs from amputation in diabetes
- New wound dressing put to the test against diabetic foot ulcers
- Silver and sound: can ultrasound push nanoparticles into diabetic wounds?
- Zapping a leg nerve: can a wearable device help stubborn ulcers heal?
- Wound dressings that trap microbes: scientists test a Drug-Free approach
- Can a traditional herbal mix save limbs from diabetic ulcers?